{"entity":{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","aka":[],"tldr":"Scorpion Therapeutics was a Boston start-up that designed a cancer pill, STX-478, aimed only at the mutated form of a growth protein called PI3K-alpha, sparing the normal form. Eli Lilly bought the programme in 2025.","summary":"Scorpion Therapeutics was a Boston precision oncology company founded in 2020 whose lead asset, STX-478, is a mutant-selective, allosteric PI3K-alpha inhibitor intended to avoid the hyperglycaemia and other toxicities of wild-type PI3K-alpha inhibition. In January 2025 Eli Lilly agreed to acquire the STX-478 programme; Lilly's first-quarter 2025 results describe the acquisition as the main driver of a 1.57 billion US dollar acquired in-process research and development charge, and the Scorpion website now redirects to Lilly's announcement. SEC Form D filings show roughly 172 million US dollars sold in 2020 offerings and a further 125.7 million US dollars sold in a 2024 offering before the sale to Lilly.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.scorpiontx.com/"},{"label":"Lilly Q1 2025 results mentioning the acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm"},{"label":"Form D (July 2024)","url":"https://www.sec.gov/Archives/edgar/data/1811858/000095012324006593/primary_doc.xml"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["pik3ca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["scorpiontx.com redirects to a Lilly investor page that returned HTTP 403, so the acquisition press release itself could not be fetched; the deal is confirmed via Lilly's SEC-filed earnings releases. Headline deal value (reported in press as up to 2.5 billion US dollars) and the reported spin-out of non-PI3K assets were not verified. Series labels for the Form D rounds are not stated in the filings."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.scorpiontx.com/","founded":2020,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2020,"amountUsd":24681250,"source":"https://www.sec.gov/Archives/edgar/data/1811858/000181185820000001/primary_doc.xml","note":"Total sold per Form D filed May 2020"},{"round":"Form D offering","year":2020,"amountUsd":146999977,"source":"https://www.sec.gov/Archives/edgar/data/1811858/000181185820000003/primary_doc.xml","note":"Total sold per Form D filed December 2020"},{"round":"Form D offering","year":2024,"amountUsd":125694186,"source":"https://www.sec.gov/Archives/edgar/data/1811858/000095012324006593/primary_doc.xml","note":"Total sold of a 150 million US dollar offering per Form D filed July 2024"},{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm","note":"Lilly's Q1 2025 results attribute most of a 1.57 billion US dollar acquired in-process R&D charge to the acquisition of Scorpion's PI3K-alpha inhibitor programme STX-478; headline deal value not verified"}],"acquiredBy":"eli-lilly"},"route":"/companies/scorpion-therapeutics/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"company":[{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/"},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}